Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer por Al B Benson, Anirban Maitra, Milind Javle, Michael Overman, Richard E Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B Mettu, Edwin R Parra, Charles D Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu

Obter o texto integral